Tus kws kho mob
QP37-18 Pharmacy Benefit Update - Brand Copaxone 20mg/mL and 40 mg/ML Non-Formulary
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 21, 2018
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 3041 - 3050 ntawm 4138
Tus kws kho mob
QP13-16 Provider Cost Data Update
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2016
Tus kws kho mob
P56-16 A New Drug, Dupilumab Will Require Prior Authorization
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 22, 2016
Tus kws kho mob
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P4-17 Addition of Drug to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 30, 2017
Tus kws kho mob
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 10, 2016
Tus kws kho mob
P56-17 Implementation of a Medical Drug Exclusions List
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 16, 2017
Tus kws kho mob
P5R1-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 05, 2017
Tus kws kho mob
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 28, 2016
Tus kws kho mob
P53-16 New Notification Requirement for Outpatient Dialysis Services for Commercial Products and Subscribers in Government Programs
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 09, 2016